These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30200073)

  • 1. Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report.
    Sampaio Vieira T; Borges Faria D; Souto Moura C; Francisco E; Barroso S; Pereira de Oliveira J
    Medicine (Baltimore); 2018 Sep; 97(36):e11878. PubMed ID: 30200073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).
    Krausz Y; Freedman N; Rubinstein R; Lavie E; Orevi M; Tshori S; Salmon A; Glaser B; Chisin R; Mishani E; J Gross D
    Mol Imaging Biol; 2011 Jun; 13(3):583-593. PubMed ID: 20652423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Added value of [
    Yoo J; Kim SH; Jeon SK; Bae JS; Han JK
    Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
    Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C
    AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.
    Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R
    Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 68Ga-DOTATOC PET/CT in comparison to 111In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report.
    Tolomeo A; Lopopolo G; Dimiccoli V; Perioli L; Modoni S; Scilimati A
    Medicine (Baltimore); 2020 Feb; 99(7):e19162. PubMed ID: 32049844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
    Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of using [
    Leupe H; Pauwels E; Vandamme T; Van den Broeck B; Lybaert W; Dekervel J; Van Herpe F; Jaekers J; Cleeren F; Hofland J; Brouwers A; Koole M; Bormans G; Van Cutsem E; Geboes K; Laenen A; Verslype C; Stroobants S; Deroose CM
    J Neuroendocrinol; 2024 Aug; 36(8):e13420. PubMed ID: 38837825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and Evaluation of [
    Dam JH; Langkjær N; Baun C; Olsen BB; Nielsen AY; Thisgaard H
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
    Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
    Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
    Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
    Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of [
    Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns.
    Krausz Y; Rubinstein R; Appelbaum L; Mishani E; Orevi M; Fraenkel M; Tshori S; Glaser B; Bocher M; Salmon A; Chisin R; Gross DJ; Freedman N
    Clin Nucl Med; 2012 Jan; 37(1):57-62. PubMed ID: 22157030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of quantitative tumor burden based on [
    Chen L; Jumai N; He Q; Liu M; Lin Y; Luo Y; Wang Y; Chen MH; Zeng Z; Zhang X; Zhang N
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):525-534. PubMed ID: 36181533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of [
    Gaertner FC; Plum T; Kreppel B; Eppard E; Meisenheimer M; Strunk H; Bundschuh RA; Sinnes JP; Rösch F; Essler M
    Nucl Med Biol; 2019; 76-77():1-9. PubMed ID: 31520872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of metastases outside the liver and abdominal lymph nodes on
    Wedin M; Janson ET; Wallin G; Sundin A; Daskalakis K
    J Neuroendocrinol; 2024 May; 36(5):e13391. PubMed ID: 38590270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.